MarketBeat
15 Sept 2026, 05:03 UTC · 9w ago
Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near
Impact · against what's priced in
Sarepta faces near-term revenue headwinds as ELEVIDYS demand stabilizes below first-half levels, with growth unlikely to accelerate until 2027. However, the pipeline's potential as a multi-platform leader is bolstered by strong DUX4 correction data in FSHD, which suggests a significant efficacy advantage over competitors.
- NVS−0.30
No priced-in read yet





